SHP Share PerformanceMore
|52 week high||5,377.0 20/09/16|
|52 week low||2,707.0 13/07/16|
|52 week change||542.5 (12.67%)|
|4 week volume||47,256,354 26/04/17|
Latest News« previous» nextMore
19/05/2017 - 15:51 StockMarketWire
Equity analysts at HSBC have downgraded their investment rating on Shire Pharmaceuticals (LON:SHP) to 'reduce' (from ...
19/05/2017 - 08:10 StockMarketWire
HSBC today downgrades its investment rating on Shire PLC (LON:SHP) to reduce (from hold) and cut its price target to 44...
18/05/2017 - 17:04 StockMarketWire
As Royal Dutch Shell (RDSB) traded ex-dividend and oil prices came under pressure, shares in the oil giant dropped sharpl...
18/05/2017 - 13:03 StockMarketWire
Shire has announced positive topline Phase 3 results for the HELP study that evaluated the efficacy and safety of subcutan...
18/05/2017 - 12:00 RNS
Shire?s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration Data to serve as basis for U.S. BLA filing expected in Q4 2017 to Q1 2018 Shire to host...
10/05/2017 - 08:40 StockMarketWire
Deutsche Bank today reaffirms its buy investment rating on Shire PLC (LON:SHP) and cut its price target to 6100p (from ...
03/05/2017 - 17:31 RNS
Director/PDMR Shareholding May 3, 2017 ? Shire plc (LSE: SHP, NASDAQ: SHPG) (the ?Company?) Notification of transactions by person discharging managerial responsibilities 1. Details of the person discharging managerial responsibilities (?PDMR?) / person closely associated them (?PCA?) a) Name Matt Walker 2. Reason for the notification a) Position / status Head...
02/05/2017 - 16:58 StockMarketWire
UK manufacturing activity rose to a three-year high in April. The purchasing managers' index increased to 57.3, up from M...
Latest discussion posts More
“Shire has announced positive topline Phase 3 results for the HELP study that evaluated the efficacy and safety of subcutaneously administered lanadelumab versus placebo over 26 ...”▼
“If it is Trump worries that were holding this stock back then hopefully they've been dispelled by his seeming inability to really implement anything that he'd like to. These ...”▼
“Yes, I think it has mainly been the threats from Trump to crack down on pharmaceutical high prices that have been holding these back. Whether or not he will ever do anything is ...”▼
Codes & Symbols
|Symbols||SHP, LSE:SHP, SHP.L, SHP:LN, LON:SHP, XLON:SHP|